Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07164443 · ClinicalTrials.gov registry record · Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Phase 3 study of Metastatic Castration-resistant Prostate Neoplasms, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 663
- Enrollment target
- 20
- Study locations
NCT07164443: Recruiting Phase 3 study of Metastatic Castration-resistant Prostate Neoplasms, sponsored by Janssen Research & Development.
NCT07164443 is a Phase 3 study of Metastatic Castration-resistant Prostate Neoplasms that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 663 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07164443, a Phase 3 study of Metastatic Castration-resistant Prostate Neoplasms, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 663 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).
Primary Outcome
OS is defined as the time from randomization to date of death due to any cause.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Pasritamig
- DRUG Best Supportive Care (BSC)
Study Locations (20)
New York
- NYU Langone Hospitals - Brooklyn
- NYU Langone Hospital Long Island - Mineola
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center - New York
Pennsylvania
- MidLantic Urology - Bala-Cynwyd
- Keystone Urology Specialists - Lancaster
- UPMC Cancer Centers - Pittsburgh
South Carolina
- Gibbs Cancer Center and Research Institute Pelham - Greer
- Carolina Urologic Research Center - Myrtle Beach
- Gibbs Cancer Center - Spartanburg
Colorado
- Rocky Mountain Cancer Centers - Aurora
- Colorado Clinical Research - Lakewood
Florida
- Bay Pines VA Healthcare System - Bay Pines
- Florida Cancer Specialists & Research Institute - Fort Myers
Oregon
- Compass Oncology - Portland
- Oregon Urology Institute - Springfield
Louisiana
- East Jefferson General Hospital - Metairie
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 663 participants |
| Start Date | 2025-09-02 |
| Est. Completion | 2028-05-30 |
| Phase | Phase 3 |
What NCT07164443 shows while recruiting
NCT07164443 is an interventional study that assigns participants to a tested intervention. The registered 663 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Metastatic Castration-resistant Prostate Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07164443 names 20 study sites across 11 states, led by New York, Pennsylvania, South Carolina.
Frequently Asked Questions
What is clinical trial NCT07164443 about?
NCT07164443 is a clinical study titled "A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)". The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with BSC in participants with metastatic castration-resistant pro...
What is the current status of trial NCT07164443?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 663 participants. The study started on 2025-09-02. Estimated completion is 2028-05-30.
What conditions does trial NCT07164443 study?
This clinical trial studies the following conditions: Metastatic Castration-resistant Prostate Neoplasms.
What interventions are being tested in trial NCT07164443?
The interventions under investigation include: Placebo (OTHER), Pasritamig (BIOLOGICAL), Best Supportive Care (BSC) (DRUG).
Who is sponsoring clinical trial NCT07164443?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07164443 being conducted?
This trial has 20 study locations across Colorado, Florida, Louisiana, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-resistant Prostate Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07164443's enrollment target sits among peer trials
663 553rd of 2000 higher than 1,448 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
- NCT05254743 · 662 participants · Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI